中国上海石门一路 288 号兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：（86-21）5298 5488 传真：（86-21）5298 5492 junhesh@junhe.com 关于长华化学科技股份有限公司 2024 年年度股东会之法律意见书 致：长华化学科技股份有限公司 君合律师事务所上海分所（以下简称"本所"）接受长华化学科技股份有限公 司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规 则》（以下简称"《股东会规则》"）等法律、法规、规范性文件（以下简称"法律、 法规"）及《长华化学科技股份有限公司章程》（以下简称"《公司章程》"）的有关 规定，按照律师行业公认的业务标准、道德规范和勤勉尽责精神，就公司 2024 年 年度股东会（以下简称"本次股东会"）有关事宜出具本法律意见书。 为出具本法律意见书之目的，本所委派律师（以下简称"本所律师"）对公司 提供的与本次股东会有关的文件和事实进行了核查和验证。在本所律师对公司提 供的有关文件进行核查和验证的过程中，本所假设： 1. ...

东吴证券股份有限公司 | 项目 | 工作内容 | | --- | --- | | 1、 公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 次 0 | | 2、 督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于 | | | 防止关联方占用公司资源的制度、募集资金管理制度、 | 是 | | 内控制度、内部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、 募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4、 公司治理督导情况 | | | （1）列席公司股东大会次数 | 1 次 | | （2）列席公司董事会次数 | 未现场列席，已审阅会议相关资料 | | （3）列席公司监事会次数 | 未现场列席，已审阅会议相关资料 | | 5、 现场检查情况 | | | （1）现场检查次数 | 1 次 | | （2）现场检查报告是否按照本所规定报送 | 是 ...

Summary of Key Points from Conference Call Records Industry or Company Involved - **Domestic Aircraft Manufacturing**: Focus on the C919 aircraft and its potential to replace Boeing's market share in Europe [2][3] - **Military Trade**: Insights into the military trade dynamics between India and Pakistan, and the implications for Chinese military exports [4][5][6] - **Pharmaceuticals**: Discussion on the global sales of semaglutide and its impact on the obesity treatment market [8][9] - **Chemical Industry**: Analysis of the price movements in the chemical sector, particularly ethylene glycol and its derivatives [12][13][14] - **Textiles**: Overview of the textile industry, particularly the impact of U.S.-China trade relations on exports [15] - **Technology and Automation**: Developments in automated equipment and smart transportation solutions [20][21] Core Points and Arguments Domestic Aircraft Manufacturing - The C919 aircraft is expected to capture part of Boeing's market share in Europe due to potential tariffs on Boeing products [2] - China Commercial Aircraft Corporation (COMAC) plans to increase C919 production capacity significantly from 75 to 200 aircraft by 2029, a 33% increase compared to 2027 [2] - The Airbus Tianjin assembly line exemplifies successful Sino-European aviation cooperation [2] Military Trade - The escalation of armed conflict between India and Pakistan has implications for military trade, with Pakistan being a major recipient of Chinese military exports [4] - China’s military products have gained a significant market share globally, with Pakistan accounting for over 50% of China's military exports from 2017 to 2024 [4] - Key companies involved in military trade include Aerospace Changfeng and other defense contractors [4][5][6] Pharmaceuticals - Semaglutide has surpassed K drug in global sales, indicating a strong market for obesity treatments [8] - Novo Nordisk reported a 19% increase in net sales, with semaglutide sales growing by 85% [8] - Related companies include Changshan Pharmaceutical and Jin Kai Biotechnology, which are involved in the production of similar drugs [9] Chemical Industry - Ethylene glycol prices have risen by 1.47%, driven by supply constraints and increased demand [12] - Danhua Technology is a key player in the ethylene glycol market, with a production capacity of 132,000 tons [12] - The chemical sector is experiencing a surge due to rising prices of various chemical products [13][14] Textiles - The U.S. Treasury's comments on trade relations may ease the impact of tariffs on textile exports [15] - Huafang Co. has a significant share of the global market for lyocell fabrics, with a focus on sustainable production [15] - The company reported that 40% of its business is linked to the U.S. market, highlighting its international exposure [15] Technology and Automation - Maiwei Co. has developed automated wafer-level hybrid bonding equipment, marking a significant advancement in manufacturing technology [20] - The company is positioned to benefit from the growing demand for advanced packaging solutions in the semiconductor industry [20] - Dayang Group's recent announcement regarding the lifting of an investigation by the U.S. Department of Commerce is expected to positively impact its export orders [21] Other Important but Possibly Overlooked Content - The potential for increased cooperation between China and Russia in various sectors, including military and technology, was mentioned [18] - The impact of geopolitical tensions on supply chains and market dynamics was highlighted, particularly in the context of the India-Pakistan conflict [10][11] - The importance of maintaining accurate and up-to-date information in rapidly changing market conditions was emphasized throughout the documents [4][5][6][12][15]

一、回购事项概述 长华化学科技股份有限公司（以下简称"公司"）于 2024 年 11 月 11 日召开 第三届董事会第十二次会议，审议通过了《关于回购公司股份方案的议案》，同意 公司使用资金总额不超过 2,000 万元（含），不低于 1,000 万元（含）的自有资金 及中国建设银行股份有限公司张家港分行提供的股票回购专项贷款以集中竞价交 易方式回购公司人民币普通股（A 股），其中专项贷款金额不超过 1,400 万元。回 购股份将用于员工持股计划或股权激励，回购的实施期限为自公司第三届董事会第 十二次会议审议通过回购方案之日起不超过 12 个月。 具体内容详见公司分别于 2024 年 11 月 12 日、12 月 4 日在巨潮资讯网披露的 《关于回购公司股份方案暨取得金融机构股票回购专项贷款承诺书的公告》（公告 编号：2024-038）、《回购股份报告书》（公告编号：2024-042）。 二、回购进展情况 根据《公司法》《证券法》《上市公司股份回购规则》《深圳证券交易所上市 公司自律监管指引第 9 号——回购股份》等法律法规和规范性文件及《公司章程》 的有关规定：在回购股份期间，上市公司应当在每个月的前三个交易 ...

智通财经5月7日电，长华化学20CM涨停，渝三峡A6连板，金丹科技、红宝丽、星华新材、联盛化学、 中毅达、江天化学、迪尔化工等多股涨超5%。 化工股再度走强 长华化学20CM涨停 ...

Summary of Key Points Core Viewpoint - The latest financing balance of the ChiNext market is 336.92 billion yuan, showing a decrease of 0.7 billion yuan compared to the previous period, with 19 stocks experiencing a financing balance growth of over 10% and 12 stocks seeing a decline of over 10% [1]. Financing Balance Overview - As of April 24, the ChiNext index fell by 0.68%, with a total margin balance of 337.83 billion yuan, down by 0.7 billion yuan from the previous trading day. The financing balance specifically is 336.92 billion yuan, a decrease of 0.7 billion yuan, while the securities lending balance is 91.3 million yuan, down by 3.22 million yuan [1]. - A total of 417 stocks saw an increase in financing balance, with 19 stocks increasing by more than 10%. The largest increase was observed in Changhua Chemical, with a financing balance of 54.14 million yuan, up by 29.08% [1][3]. Stocks with Increased Financing Balance - The stocks with significant financing balance increases include: - Changhua Chemical: 54.14 million yuan, +29.08%, closing price 19.90 yuan, +1.38% [3]. - Zhonghuan Hailu: 71.04 million yuan, +23.90%, closing price 21.61 yuan, -5.67% [3]. - Weihai De: 92.84 million yuan, +23.53%, closing price 29.20 yuan, -4.58% [3]. - The average increase for stocks with over 10% growth was 1.85%, with notable performers including Jinkai Biotechnology, Zhaomin Technology, and Haitai Technology, with increases of 16.88%, 14.03%, and 6.96% respectively [1][3]. Stocks with Decreased Financing Balance - A total of 520 stocks experienced a decrease in financing balance, with 12 stocks declining by more than 10%. The largest decrease was seen in Pulaide, with a financing balance of 19.71 million yuan, down by 24.07% [4]. - Other notable declines include: - Jingang Photovoltaic: 33.29 million yuan, -23.39% [4]. - Tianyuan Pet: 68.45 million yuan, -19.54% [4]. Capital Flow Insights - On April 24, among the stocks with increased financing balance, 12 stocks saw net inflows of main funds, with Jinkai Biotechnology leading at 137 million yuan, followed by Jinyang Co. at 66.30 million yuan and Shengyuan Environmental Protection at 32.23 million yuan [2]. - Conversely, 7 stocks experienced net outflows, with Zhaomin Technology leading at 129 million yuan, followed by New Aluminum Era at 74.46 million yuan and Hengbo Co. at 61.49 million yuan [2].

Core Viewpoint - The company is a leading manufacturer of polyether polyols in China, focusing on innovation and market expansion despite facing challenges in profitability due to increased competition and fluctuating raw material prices [3][7][10]. Company Overview - The company specializes in the research, production, and sales of polyether products, classified under the organic chemical raw materials manufacturing industry [3]. - Its main products include soft foam polyether, CASE polyether, and specialty polyether, with soft foam polyether being the core product [5][6]. Financial Performance - In 2024, the company achieved a sales volume of 325,000 tons, representing a year-on-year increase of 18.61%, and generated operating revenue of 3,049.89 million yuan, up 12.47% from the previous year [7][9]. - The company's net profit attributable to shareholders was 58.16 million yuan, a significant decline of 49.90% compared to the previous year, primarily due to reduced profit margins on its main product, POP [10]. Market Dynamics - The polyether industry is experiencing intensified competition, with market share increasingly concentrated among leading manufacturers [6][7]. - Economic slowdowns and geopolitical tensions have impacted demand and export costs, while government policies aimed at stimulating sectors like real estate and automotive are expected to positively influence demand for polyether products [7][9]. Innovation and Development - The company emphasizes technological innovation and management model innovation, investing in R&D to enhance its competitive edge [8][10]. - In 2024, R&D investment reached 113.54 million yuan, a 10.74% increase, resulting in the acquisition of 6 new patents and 15 new patent applications [10]. Corporate Governance and Social Responsibility - The company integrates environmental, social, and governance (ESG) principles into its core strategy, focusing on green supply chain upgrades and sustainable development [8]. - It has implemented a share repurchase plan to enhance investor confidence, with a total repurchase amount of approximately 15.02 million yuan by the end of the reporting period [14][15].

Core Insights - The company reported an increase in revenue for 2024, but a significant decline in net profit, highlighting both growth efforts and challenges faced in a competitive market environment [1] Financial Performance Summary - Revenue for 2024 reached 3,049,887,686.76 yuan, a 12.47% increase from 2,711,764,247.22 yuan in 2023, indicating successful market expansion [2] - Main business revenue accounted for 98.68% of total revenue, with POP product revenue at 2,088,728,951.79 yuan, up 21.54% year-on-year, serving as a key growth driver [2] - Net profit attributable to shareholders was 58,155,149.65 yuan, down 49.90% from 116,077,686.46 yuan in 2023, primarily due to intensified industry competition and fluctuating raw material prices [2] - Deducted non-recurring gains, net profit was 52,356,694.52 yuan, a 53.90% decrease from 113,561,612.49 yuan in 2023, indicating pressure on core business profitability [2] - Basic earnings per share fell to 0.41 yuan from 0.97 yuan, a 57.73% decline, reflecting weakened profitability and reduced shareholder returns [2] Expense Analysis - Sales expenses were stable at 36,708,286.92 yuan, a slight increase of 1.00% from 36,343,774.57 yuan in 2023, indicating consistent marketing investment [3] - Management expenses rose by 9.28% to 34,855,569.45 yuan, likely due to business scale expansion [3] - Financial expenses decreased significantly by 225.68% to -5,016,483.35 yuan, attributed to increased foreign exchange gains and interest income [3] - R&D expenses surged by 75.29% to 20,235,026.79 yuan, reflecting a commitment to innovation and competitive advantage [3] Cash Flow Performance - Net cash flow from operating activities was 66,859,990.90 yuan, down 49.25% from 131,750,661.71 yuan in 2023, due to increased cash outflows [4] - Net cash flow from investing activities improved to 24,224,193.96 yuan from -690,456,437.71 yuan, driven by significant changes in financial product transactions [4] - Net cash flow from financing activities was -80,057,999.38 yuan, a decrease from 812,539,281.36 yuan in 2023, reflecting reduced fundraising activities [4] R&D and Talent Investment - The company increased R&D investment to 113,536,361.25 yuan, representing 3.72% of revenue, with a focus on process improvement and technology innovation [5] - The number of R&D personnel grew by 15.00% from 40 to 46, with an increase in the proportion of staff holding bachelor's degrees [6] Market Competition and Risks - The polyether industry is highly competitive, with the company facing pressure on profit margins due to market fluctuations and raw material price volatility [7][8] - The company holds a 24.92% market share in the domestic POP product market, ranking second, but must continue to optimize product structure and enhance value [7] - New projects, such as the "carbon dioxide polyether and high-performance polyol project," may face challenges in market expansion and profitability [9]

一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1300 | 0.1600 | -18.75 | 0.1900 | | 每股净资产（元） | 10.25 | 10.47 | -2.1 | 4.98 | | 每股公积金(元) | 5.96 | 5.95 | 0.17 | 0.41 | | 每股未分配利润(元) | 3.01 | 3.17 | -5.05 | 3.21 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 5.79 | 6.62 | -12.54 | 5.36 | | 净利润(亿元) | 0.19 | 0.22 | -13.64 | 0.2 | | 净资产收益率(%) | 1.31 | 1.51 | -13.25 | 3.86 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 1398.07万股，累计占流通股比： 26.15 ...

长华化学科技股份有限公司 内部控制审计报告 二〇二四年度 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 长华化学科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了长华化学科技股份有限公司（以下简称长华化学） 2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是长华化学董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、 内部控制的固有局限性 内部控制审计报告 信会师报字[2025]第 ZA11078 号 内控审计报告 第1页 四、 财务报告内部控制审计意见 我们认为，长华化学于 2024 年 12 月 31 ...